Publications

Day C.J, Favuzza P, Bielfeld S, Haselhorst T, Seefeldt L, Hauser J, Shewell L.K, Flück C, Poole J, Jen F.E.-C, Schäfer A, Dangy J.-P, Gilberger T.-W, França C.T, Duraisingh M.T, Tamborrini M, Brancucci N.M.B, Grüring C, Filarsky M, Jennings M.P, Pluschke G. The essential malaria protein PfCyRPA targets glycans to invade erythrocytes. Cell Rep. 2024;43(4):114012. DOI: 10.1016/j.celrep.2024.114012

Pluschke G, Warryn L. How our molecular understanding of the pathogenesis of Mycobacterium ulcerans infection can improve diagnosis of Buruli ulcer. Expert Rev Mol Diagn. 2024(1-2):1-4. DOI: 10.1080/14737159.2023.2294333

Sakakibara Y, Konishi M, Ueno T, Murase C, Miyamoto Y, Ato M, de Souza D.K, Biamonte M, Pluschke G, Yotsu R.R. Pilot use of a mycolactone-specific lateral flow assay for Buruli ulcer: a case report from Japan. J Clin Tuberc Other Mycobact Dis. 2024;36:100469. DOI: 10.1016/j.jctube.2024.100469

Ispasanie E, Muri L, Schmid M, Schubart A, Thorburn C, Zamurovic N, Holbro T, Kammüller M, Pluschke G. In vaccinated individuals serum bactericidal activity against B meningococci is abrogated by C5 inhibition but not by inhibition of the alternative complement pathway. Front Immunol. 2023;14:1180833. DOI: 10.3389/fimmu.2023.1180833

Jen F.E, Abrahams J.L, Schulz B.L, Lamelas Cabello A, Pluschke G, Jennings M.P. High-frequency changes in pilin glycosylation patterns during Neisseria meningitidis serogroup a meningitis outbreaks in the African meningitis belt. ACS Infect Dis. 2023;9:1451–1457. DOI: 10.1021/acsinfecdis.3c00149

Junghanss T, Pluschke G. Mycobacterium ulcerans disease (Buruli ulcer). In: Farrar J,Hotez P.J,Junghanss T,Kang G,Lalloo D,White N.J,Garcia P.J, eds. Manson's Tropical Diseases, 557-568. Amsterdam: Elsevier, 2023. DOI: 10.1016/B978-0-7020-7959-7.00048-8

Mäser P, Bernhard S, Brun R, Burri C, Gagneux S, Hetzel M.W, Kaiser M, Lengeler C, Pluschke G, Reus E, Rottmann M, Utzinger J, Warryn L, Wittlin S, Keiser J. Key contributions by the Swiss Tropical and Public Health Institute towards new and better drugs for tropical diseases. Chimia (Aarau). 2023;77(9):593-606. DOI: 10.2533/chimia.2023.593

Tamborrini M, Schäfer A, Hauser J, Zou L, Paris D.H, Pluschke G. The malaria blood stage antigen PfCyRPA formulated with the TLR-4 agonist adjuvant GLA-SE elicits parasite growth inhibitory antibodies in experimental animals. Malar J. 2023;22:210. DOI: 10.1186/s12936-023-04638-8

Warryn L, Pluschke G. Repurposing of tuberculosis drug candidates for the treatment of Mycobacterium ulcerans disease. Chimia (Aarau). 2023;77(9):577-581. DOI: 10.2533/chimia.2023.577

Day C.J, Poole J, Pluschke G, Jennings M.P. Investigation of Mycobacterium ulcerans glycan interactions using glycan array and surface plasmon resonance. In: Pluschke G,Röltgen K, eds. Mycobacterium ulcerans:, 29-40. New York, NY: Humana, 2022. (Methods in molecular biology: 2387). DOI: 10.1007/978-1-0716-1779-3_4

Eddyani M, Affolabi D, Ablordey A, Eyangoh S, Pluschke G. Laboratory investigations in Buruli ulcer. In: Nunzi E,Massone C,Portaels F, eds. Leprosy and Buruli ulcer: a practical guide, 443-454. Cham: Springer Nature, 2022. DOI: 10.1007/978-3-030-89704-8_41

Fernandes B, Sousa M, Castro R, Schäfer A, Hauser J, Schulze K, Amacker M, Tamborrini M, Pluschke G, Alves P.M, Fleury S, Roldão A. Scalable process for high-yield production of PfCyRPA using insect cells for inclusion in a malaria virosome-based vaccine candidate. Front Bioeng Biotechnol. 2022;10:879078. DOI: 10.3389/fbioe.2022.87907

Hall B.S, Dos Santos S.J, Hsieh L.T, Manifava M, Ruf M.T, Pluschke G, Ktistakis N, Simmonds R.E. Inhibition of the SEC61 translocon by mycolactone induces a protective autophagic response controlled by EIF2S1-dependent translation that does not require ULK1 activity. Autophagy. 2022;18(4):841-859. DOI: 10.1080/15548627.2021.1961067

Hsieh L.T, Dos Santos S.J, Hall B.S, Ogbechi J, Loglo A.D, Salguero F.J, Ruf M.T, Pluschke G, Simmonds R.E. Aberrant stromal tissue factor localisation and mycolactone-driven vascular dysfunction, exacerbated by IL-1β, are linked to fibrin formation in Buruli ulcer lesions. PLoS Pathog. 2022;18:e1010280. DOI: 10.1371/journal.ppat.1010280

Leuenberger A, Koné B.V, N'krumah R.T.A.S, Koffi D.Y, Bonfoh B, Utzinger J, Pluschke G. Perceived water-related risk factors of Buruli ulcer in two villages of south-central Côte d’Ivoire. PLoS Negl Trop Dis. 2022;16(12):e0010927. DOI: 10.1371/journal.pntd.0010927

Muri L, Schubart A, Thorburn C, Zamurovic N, Holbro T, Kammüller M, Pluschke G, Ispasanie E. Inhibition of the different complement pathways has varying impacts on the serum bactericidal activity and opsonophagocytosis against Haemophilus influenzae type b. Front Immunol. 2022;13:1020580. DOI: 10.3389/fimmu.2022.1020580

Pluschke G,Röltgen K, eds. Mycobacterium ulcerans: methods and protocols. New York, NY: Humana Press, 2022. DOI: 10.1007/978-1-0716-1779-3

Pluschke G, Röltgen K. Overview: development of drugs against Mycobacterium ulcerans. In: Pluschke G,Röltgen K, eds. Mycobacterium ulcerans:, 185-187. New York, NY: Humana, 2022. (Methods in molecular biology: 2387). DOI: 10.1007/978-1-0716-1779-3_17

Pluschke G, Röltgen K. Preface. In: Pluschke G,Röltgen K, eds. Mycobacterium ulcerans:, V-VI. New York, NY: Humana, 2022. DOI: 10.1007/978-1-0716-1779-3_1

Portaels F, Pluschke G. History and geographic distribution of Buruli ulcer. In: Nunzi E,Massone C,Portaels F, eds. Leprosy and Buruli ulcer: a practical guide, 421-430. Cham: Springer Nature, 2022. DOI: 10.1007/978-3-030-89704-8_39

Röltgen K, Johnson P.D.R, Pluschke G. Epidemiology of Buruli ulcer. In: Nunzi E,Massone C,Portaels F, eds. Leprosy and Buruli ulcer. A practical guide, 541-550. Cham: Springer Nature, 2022. DOI: 10.1007/978-3-030-89704-8_47

Röltgen K, Pluschke G. Overview: Mycobacterium ulcerans disease (Buruli ulcer). In: Pluschke G,Röltgen K, eds. Mycobacterium ulcerans:, 3-6. New York, NY: Humana, 2022. (Methods in molecular biology: 2387). DOI: 10.1007/978-1-0716-1779-3_1

Röltgen K, Pluschke G. Overview: mycolactone, the macrolide toxin of Mycobacterium ulcerans. In: Pluschke G,Röltgen K, eds. Mycobacterium ulcerans:, 105-108. New York, NY: Humana, 2022. (Methods in molecular biology: 2387). DOI: 10.1007/978-1-0716-1779-3_11

Toppino S, Koffi D.Y, Koné B.V, N'Krumah R.T.A.S, Coulibaly I.D, Tobian F, Pluschke G, Stojkovic M, Bonfoh B, Junghanss T. Community-based wound management in a rural setting of Côte d'Ivoire. PLoS Negl Trop Dis. 2022;16(10):e0010730. DOI: 10.1371/journal.pntd.0010730

Toppino S, N'Krumah R.T.A.S, Koné B.V, Koffi D.Y, Coulibaly I.D, Tobian F, Pluschke G, Stojkovic M, Bonfoh B, Junghanss T. Skin wounds in a rural setting of Côte d'Ivoire: population-based assessment of the burden and clinical epidemiology. PLoS Negl Trop Dis. 2022;16(10):e0010608. DOI: 10.1371/journal.pntd.0010608

Warryn L, Pluschke G. Efficacy of an acid-oxidising solution against Mycobacterium ulcerans. Antimicrob Agents Chemother. 2022;66(1):e00870-21. DOI: 10.1128/AAC.00870-21

Brunetti G, Padovani F, De Pastina A, Rotella C, Monahan Am, Hoffman S.L, Jongo S.A, Abdulla S, Corradin G, Pluschke G, Daubenberger C, Hegner M. Nanotechnological immunoassay for rapid label-free analysis of candidate malaria vaccines. Nanoscale. 2021;13(4):2338-2349. DOI: 10.1039/D0NR08083G

Day C.J, Röltgen K, Pluschke G, Jennings M.P. The cell surface protein MUL_3720 confers binding of the skin pathogen Mycobacterium ulcerans to sulfated glycans and keratin. PLoS Negl Trop Dis. 2021;15(2):e0009136. DOI: 10.1371/journal.pntd.0009136

Ispasanie E, Muri L, Schubart A, Thorburn C, Zamurovic N, Holbro T, Kammüller M, Pluschke G. Alternative complement pathway inhibition does not abrogate meningococcal killing by serum of vaccinated individuals. Front Immunol. 2021;12:747594. DOI: 10.3389/fimmu.2021.747594

Please H.R, Vas Nunes J.H, Patel R, Pluschke G, Tholley M, Ruf M.T, Bolton W, Scott J.A, Grobusch M.P, Bolkan H.A, Brown J.M, Jayne D.G. Chronic wounds in Sierra Leone: searching for Buruli ulcer, a NTD caused by Mycobacterium ulcerans, at Masanga Hospital. PLoS Negl Trop Dis. 2021;15(10):e0009862. DOI: 10.1371/journal.pntd.0009862

Warryn L, Dangy J.P, Gersbach P, Gehringer M, Altmann K.H, Pluschke G. An antigen capture assay for the detection of mycolactone, the polyketide toxin of Mycobacterium ulcerans. J Immunol. 2021;206(11):2753-2762. DOI: 10.4049/jimmunol.2001232

Borel N, Sauer-Durand A.M, Hartel M, Kuratli J, Vaupel P, Scherr N, Pluschke G. wIRA: hyperthermia as a treatment option for intracellular bacteria, with special focus on Chlamydiae and Mycobacteria. Int J Hyperthermia. 2020;37:373-383. DOI: 10.1080/02656736.2020.1751312

Chaguza C, Yang M, Cornick J.E, du Plessis M, Gladstone R.A, Kwambana-Adams B.A, Lo S.W, Ebruke C, Tonkin-Hill G, Peno C, Senghore M, Obaro S.K, Ousmane S, Pluschke G, Collard J.M, Sigaùque B, French N, Klugman K.P, Heyderman R.S, McGee L, Antonio M, Breiman R.F, von Gottberg A, Everett D.B, Kadioglu A, Bentley S.D. Bacterial genome-wide association study of hyper-virulent pneumococcal serotype 1 identifies genetic variation associated with neurotropism. Commun Biol. 2020;3:559. DOI: 10.1038/s42003-020-01290-9

Röltgen K, Pluschke G, Spencer J.S, Brennan P.J, Avanzi C. The immunology of other mycobacteria: M. ulcerans, M. leprae. Semin Immunopathol. 2020;42(3):333-353. DOI: 10.1007/s00281-020-00790-4

Röltgen K, Pluschke G. Buruli ulcer: the efficacy of innate immune defense may be a key determinant for the outcome of infection with Mycobacterium ulcerans. Front Microbiol. 2020;11:1018. DOI: 10.3389/fmicb.2020.01018

Tamborrini M, Hauser J, Schäfer A, Amacker M, Favuzza P, Kyungtak K, Fleury S, Pluschke G. Vaccination with virosomally formulated recombinant CyRPA elicits protective antibodies against Plasmodium falciparum parasites in preclinical in vitro and in vivo models. Vaccines. 2020;5:9. DOI: 10.1038/s41541-020-0158-9

Thomas S.S, Kalia N.P, Ruf M.T, Pluschke G, Pethe K. Toward a single-dose cure for Buruli ulcer. Antimicrob Agents Chemother. 2020;64(9):e00727-20. DOI: 10.1128/AAC.00727-20

Vandelannoote K, Pluschke G, Bolz M, Bratschi M.W, Kerber S, Stinear T.P, de Jong B.C. Introduction of Mycobacterium ulcerans disease in the Bankim Health District of Cameroon follows damming of the Mapé river. PLoS Negl Trop Dis. 2020;14(9):e0008501. DOI: 10.1371/journal.pntd.0008501

Warryn L, Dangy J.P, Gersbach P, Gehringer M, Schäfer A, Ruf M.T, Ruggli N, Altmann K.H, Pluschke G. Development of an ELISA for the quantification of mycolactone, the cytotoxic macrolide toxin of Mycobacterium ulcerans. PLoS Negl Trop Dis. 2020;14(6):e0008357. DOI: 10.1371/journal.pntd.0008357

Gehringer M, Mäder P, Gersbach P, Pfeiffer B, Scherr N, Dangy J.P, Pluschke G, Altmann K.H. Configurationally stabilized analogs of M. ulcerans exotoxins mycolactones A and B reveal the importance of side chain geometry for mycolactone virulence. Org Lett. 2019;21(15):5853-5857. DOI: 10.1021/acs.orglett.9b01947